Promptly treating prostate cancer bone metastases with the newest medication can help change your prognosis dramatically, Tagawa says. “There are men who do well for decades,” he says.

Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).

Among common tumors, prostate cancer, breast cancer, thyroid cancer, lung cancer and kidney cancer have a higher incidence of bone metastasis, accounting for more than 80% of all bone metastatic ...

PET/CT scans using an experimental prostate-specific membrane antigen (PSMA) imaging agent can identify SC nodal metastasis ...

Stage 4 prostate cancer is the most advanced stage of the ... Radiation may also be used for bone metastases to decrease pain ...

Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.

Short-term ADT especially benefitted patients with a baseline PSA level of more than 2 ng/mL, a PSA doubling time of less than 3 months, and a higher metastatic stage, presumably because they were ...

Further tests, such as CT scans and bone scans, may be performed to determine whether prostate ... the extent of metastasis, appearance under the microscope and response of the cancer to initial ...

A new study investigates the utility of whole-body magnetic resonance imaging for detecting lymph and bone metastases in those with high-risk prostate cancer. Visit us on Facebook. Opens in a new ...